stockportfolio.pro
Harmony Biosciences Holdings, Inc. (HRMY)
Healthcare · Biotechnology · NasdaqGM
Harmony Biosciences Holdings, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.00M | $159.74M | $305.44M | $437.86M | $582.02M | $714.73M | $868.45M |
| Gross profit | $4.42M | $132.00M | $249.92M | $354.37M | $460.79M | $557.92M | $670.11M |
| Net income | $-151.98M | $-36.94M | $34.60M | $181.47M | $128.85M | $145.49M | $158.69M |
| Net margin | -2535.1% | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
Source: Harmony Biosciences Holdings, Inc. SEC filings (10-K).
Explore 7 years of Harmony Biosciences Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HRMY in your portfolio →
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc. — frequently asked questions
What is Harmony Biosciences Holdings, Inc.'s revenue?
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.45M for fiscal year 2025, up 21.5% from the prior year, according to its SEC filings.
Is Harmony Biosciences Holdings, Inc. profitable?
Yes. HRMY earned net income of $158.69M in fiscal 2025, a net margin of 18.3%.
What is HRMY's P/E ratio?
Harmony Biosciences Holdings, Inc. trades at a price-to-earnings ratio of about 14.3 based on the latest data in our nightly-refreshed cache.
How fast is Harmony Biosciences Holdings, Inc. growing?
HRMY's revenue grew at roughly 40.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Harmony Biosciences Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.